Evidence map›Paper›PMID 41561142›Full record

ArticleNeuroimage. Reports2026

PyCaret machine learning library with three preprocessing steps after eLORETA source estimation predicts Alzheimer's disease.

Yasunori Aoki, Rei Takahashi, Roberto D Pascual-Marqui, Masahiro Hata, Shun Takahashi, Ryouhei Ishii, Masao Iwase, Mariko Maenishi, Young-Ok Kim, Yuki Yamamoto and 4 more

Abstract read
In one paragraph

Article in Neuroimage. Reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Yasunori AokiDepartment of Psychiatry, Nippon Life Hospital, Osaka, Japan.
Rei TakahashiDepartment of Psychiatry, Nippon Life Hospital, Osaka, Japan.
Roberto D Pascual-MarquiThe KEY Institute for Brain-Mind Research, University Hospital of Psychiatry, Zurich, Switzerland.
Masahiro HataDepartment of Psychiatry, Graduate School of Medicine, Osaka University, Suita, Japan.
Shun TakahashiDepartment of Psychiatry, Graduate School of Medicine, Osaka University, Suita, Japan.
Ryouhei IshiiGraduate School of Comprehensive Rehabilitation, Osaka Prefecture University, Osaka, Japan.
Masao IwaseOsaka Psychiatric Research Center, Osaka Psychiatric Medical Center, Osaka, Japan.
Mariko MaenishiDepartment of Psychiatry, Nippon Life Hospital, Osaka, Japan.
Young-Ok KimDepartment of Psychiatry, Nippon Life Hospital, Osaka, Japan.
Yuki YamamotoHuman Brain Function Center, Nippon Life Hospital, Osaka, Japan.
Sakura HikidaHuman Brain Function Center, Nippon Life Hospital, Osaka, Japan.
Kana MaruyamaDepartment of Psychiatry, Nippon Life Hospital, Osaka, Japan.
Etsuro MoriHuman Brain Function Center, Nippon Life Hospital, Osaka, Japan.
Manabu IkedaDepartment of Psychiatry, Graduate School of Medicine, Osaka University, Suita, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Alzheimer's disease (AD) -the most common form of dementia- begins with mild memory loss and gradually progresses, eventually resulting in a generalized loss of brain function. The pathological changes of AD in the brain cortex begin decades before the onset of symptoms. Improvements in lifestyle habits and disease-modifying treatments before the onset of the disease have been shown to help prevent or delay the onset of AD. However, diagnosis of AD is difficult at the early stage -or even at the prodromal stage [i.e., mild cognitive impairment due to AD (MCIAD)]- since normal aging and other types of dementia also involve memory impairment. Therefore, there is an urgent need to identify markers for the detection of AD at the early stage or pre-onset stage. In this study, we applied exact low-resolution brain electromagnetic tomography (eLORETA) as the source estimation method to electroencephalography (EEG) data. We obtained cortical electrical activity in 96 drug-free AD patients and 147 healthy subjects to train the final model, in addition to activity for 21 MCIAD patients and seven healthy subjects for the purpose of its evaluation. We then applied the low-code machine learning library of PyCaret, with three preprocessing steps (subject-wise normalization, age-difference correction, and log-transformation) to the eLORETA data of AD and healthy subjects. Of the many machine learning classification models used, the linear discriminant analysis (LDA) model showed the highest accuracy, identifying 10 AD patients and 15 healthy subjects with an accuracy of 100.0 %. The LDA model of eLORETA has high transparency and we visualized the discriminant function of the LDA final model using Viewer in eLORETA. Cortical electrical activities in the delta, theta and alpha frequency bands increased in the right dorsolateral prefrontal cortex (DLPFC) regions, as the degree of AD increased (Figs. 2-4). Cortical electrical activity in the beta frequency band decreased in the posterior cingulate cortex (PCC) regions, as the degree of AD increased (Fig. 5) Furthermore, the LDA final model correctly identified 21 MCIAD patients and seven healthy subjects with an accuracy of 96.4 %. Our findings indicate that the LDA final model of eLORETA had the capacity to detect physiological features of AD in EEG data, even before the onset of the disease. Overall, PyCaret with three preprocessing steps after eLORETA source estimation can create an accurate EEG classification model, which makes a significant contribution to the early detection of AD among the many individuals in the general population who remain undiagnosed.

Indexed as

Alzheimer's diseaseElectroencephalography (EEG)Exact low-resolution electromagnetic tomography (eLORETA)Linear discriminant analysisMachine learningPyCaret

Identifiers

PMID41561142
PMCPMC12813306

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.